- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
TB4 can protect cornea against oxidative damage
Administering TB4 (Thymosin Beta 4, RegeneRx) up-regulates anti-oxidative enzymes in human corneal epithelial cells, helping to protect the cornea and resist oxidative damage, according to researchers.
Bethesda, MD-Administering TB4 (Thymosin Beta 4, RegeneRx) up-regulates anti-oxidative enzymes in human corneal epithelial cells, helping to protect the cornea and resist oxidative damage, according to a study done by researchers at the Institute of Biopharmaceutical Science, National Yang-Ming University, Tapei, Taiwan.
The researchers believe that TB4's ability to protect cells against oxidative damage is due to cellular internalization, or the ability to migrate inside cells, which they said is essential for TB4's protective effects.
"This interesting study from an independent research group in Taiwan further expands the research we and others have conducted and shows yet again TB4's effects in protecting and repairing tissues-in this case the cornea," said Gabriel Sosne, MD, PhD, assistant professor of ophthalmology at Wayne State University School of Medicine and the Kresge Eye Institute in Detroit, and a member of the RegeneRx Medical and Scientific Advisory Board.
